Bayer nets FDA’s priority review for cancer drug in U.S.
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
Pharmaceuticals, Biotechnology and Life Sciences
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
Sanofi’s Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.
J&J’s DePuy Synthes Products, Inc. has bought asset and signed development agreement with Interventional Spine, Inc., a privately held manufacturer…
Eli Lilly’s subsidiary Elanco US has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines…
Allergan has won FDA’s approval to sell its breast implants in US.
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.
Analytical company Eurofins Scientific has broadened its testing facilities in Spain, as it is about to buy a Spanish pharmaceutical company Villapharma Research SL.